[go: up one dir, main page]

MXPA02012039A - Composiciones en polvo. - Google Patents

Composiciones en polvo.

Info

Publication number
MXPA02012039A
MXPA02012039A MXPA02012039A MXPA02012039A MXPA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A
Authority
MX
Mexico
Prior art keywords
drying
powder
compositions
prepared
spray
Prior art date
Application number
MXPA02012039A
Other languages
English (en)
Inventor
Steven Joseph Prestrelski
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of MXPA02012039A publication Critical patent/MXPA02012039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe in polvo de flujo libre formador de gel adecuado para su uso como una vacuna que se prepara por secado por rociado o secado por congelacion y rociado de una suspension acuosa que contiene un antígeno absorbido en un adyuvante de una sal de aluminio o una sal de calcio, un sacárido, un aminodcido o una sal del mismo, y una substancia coloidal. El polvo para los propositos de vacuna, tambidn se prepara por secado por congelacion y rociado de una suspension acuosa de tal adyuvante que tiene un antígeno absorbido en él. Se describen también los procesos para la formacion de estas composiciones en polvo, así como los métodos de uso de las composiciones en un procedimiento de vacunacion.
MXPA02012039A 2000-06-08 2001-06-08 Composiciones en polvo. MXPA02012039A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21058100P 2000-06-08 2000-06-08
US59077700A 2000-06-08 2000-06-08
PCT/US2001/018494 WO2001093829A2 (en) 2000-06-08 2001-06-08 Powder compositions

Publications (1)

Publication Number Publication Date
MXPA02012039A true MXPA02012039A (es) 2003-06-06

Family

ID=26905296

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012039A MXPA02012039A (es) 2000-06-08 2001-06-08 Composiciones en polvo.

Country Status (11)

Country Link
EP (1) EP1289494A2 (es)
JP (1) JP2003535119A (es)
KR (1) KR20030020294A (es)
CN (1) CN1438874A (es)
AU (1) AU2001275371B9 (es)
BR (1) BR0111494A (es)
CA (1) CA2412197A1 (es)
IL (1) IL153241A0 (es)
MX (1) MXPA02012039A (es)
NZ (2) NZ552576A (es)
WO (1) WO2001093829A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101412A2 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
US20030186271A1 (en) * 2001-11-19 2003-10-02 Robin Hwang Pharmaceutical compositions in particulate form
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
AU2005289471A1 (en) * 2004-09-28 2006-04-06 Alza Corporation Stabilization of alum-adjuvanted immunologically active agents
BRPI0612496A2 (pt) * 2005-06-27 2010-11-23 Applied Thin Films Inc microesferas baseadas em fosfato de alumìnio
RU2008117396A (ru) 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) Твердая вакцинная композиция
WO2007053781A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
AU2008231072B2 (en) * 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
KR101540920B1 (ko) * 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 항원-애주번트 조성물 및 방법
AU2009221180B2 (en) * 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
CA2738621C (en) 2008-10-02 2017-01-31 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
EP2898890B1 (en) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisation of viral particles
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
BR112012025044A2 (pt) * 2010-03-31 2016-06-21 Stabilitech Ltd método para conservar adjuvantes de alum e vacinas com adjuvantes de alum
US11311610B2 (en) 2010-11-01 2022-04-26 University Of Technology Sydney Immune-modulating agents and uses therefor
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
BR112014020930A2 (pt) * 2012-03-05 2017-06-27 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
KR101441539B1 (ko) * 2013-04-01 2014-09-18 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 흡습성이 개선된 접착제 조성물 및 이의 제조방법
CN103641886B (zh) * 2013-11-26 2015-07-29 精晶药业股份有限公司 一种丙谷二肽的精制方法
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
EP0676088A1 (en) * 1992-12-28 1995-10-11 YU, Shih-Chiang Non-volatile semiconductor memory cell
ATE218884T1 (de) * 1993-01-08 2002-06-15 Csl Ltd Impfstoffpräparate
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
RU2096042C1 (ru) * 1996-11-06 1997-11-20 Виктор Иванович Ситьков Способ получения поливалентной вакцины против лептоспироза животных
IL136488A0 (en) * 1997-12-02 2001-06-14 Powderject Vaccines Inc Transdermal delivery of particulate vaccine compositions

Also Published As

Publication number Publication date
AU7537101A (en) 2001-12-17
BR0111494A (pt) 2004-01-13
WO2001093829A2 (en) 2001-12-13
CA2412197A1 (en) 2001-12-13
CN1438874A (zh) 2003-08-27
JP2003535119A (ja) 2003-11-25
IL153241A0 (en) 2003-07-06
EP1289494A2 (en) 2003-03-12
NZ523103A (en) 2005-08-26
KR20030020294A (ko) 2003-03-08
NZ552576A (en) 2008-06-30
AU2001275371B9 (en) 2007-06-07
WO2001093829A3 (en) 2002-06-13
AU2001275371B2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
MXPA02012039A (es) Composiciones en polvo.
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
ES2313881T3 (es) Formulaciones de vacunas frente al papilomavirus humano.
GB0118249D0 (en) Histidine vaccines
JP2002501904A (ja) ワクチン
RU2004122632A (ru) Лиофилизированный препарат, содержащий антитела против рецептора egf
JP2000502672A (ja) 生ワクチンの安定化剤
CA2368391A1 (en) Human papillomavirus vaccine with disassembled and reassembled virus-like particles
PL1951299T3 (pl) Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
WO2000023105A3 (en) Adjuvant systems and vaccines
AU2008225501B2 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
HUP0303278A2 (hu) Fagyasztva szárított pantoprazol készítmény, eljárás az előállítására és pantoprazol injekció
CA2282779A1 (en) Formulation comprising an antigen, an adjuvant and an amino acid for use in immunization.
AU2011234268B2 (en) Method for preserving alum adjuvants and alum-adjuvanted vaccines
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
Colombani et al. Biomaterials and oxygen join forces to shape the immune response and boost COVID‐19 vaccines
JP2004505992A5 (es)
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
JP2017509713A5 (es)
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
RU2007110768A (ru) Способ получения препарата для лечения радиационных поражений организма и способ его применения
HK1217670A1 (zh) Albu-bche調配物、其製造方法和用途
WO2023092090A8 (en) Immunogenic fusion protein compositions and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration